Add to ORKGThe Author(s) 2014. This article is published with open access at Springerlink.com Introduction: There is scant real-world information on switching treatment for anemia associated with chronic kidney disease (CKD) from methoxy polyethylene glycol-epoetin beta (PEG-Epo) to darbepoetin alf
BackgroundErythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney ...
BackgroundErythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney ...
Recombinant human erythropoietin (epoetin) has been available for the treatment of renal anemia for ...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
Background Anemia management in non-dialysis-dependent chronic kidney disease (CKD) patients is asso...
Naro Ohashi1, Yukitoshi Sakao2, Hideo Yasuda1, Akihiko Kato2, Yoshihide Fujigaki11Internal Medicine ...
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-ep...
Background: In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ESA-naï...
Background: In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ESA-naï...
<i>Background:</i> In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ...
Background: In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ESA-na\...
The introduction of erythropoiesis-stimulating agents (ESAs) into everyday clinical practice has gre...
BACKGROUND: Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of...
BackgroundDarbepoetin alfa is a new erythropoietic protein with a three-fold longer half-life than r...
BackgroundErythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney ...
BackgroundErythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney ...
Recombinant human erythropoietin (epoetin) has been available for the treatment of renal anemia for ...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This...
Background Anemia management in non-dialysis-dependent chronic kidney disease (CKD) patients is asso...
Naro Ohashi1, Yukitoshi Sakao2, Hideo Yasuda1, Akihiko Kato2, Yoshihide Fujigaki11Internal Medicine ...
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-ep...
Background: In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ESA-naï...
Background: In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ESA-naï...
<i>Background:</i> In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ...
Background: In non-dialysis patients (ND-CKD), C.E.R.A. has been extensively investigated in ESA-na\...
The introduction of erythropoiesis-stimulating agents (ESAs) into everyday clinical practice has gre...
BACKGROUND: Several studies with erythropoiesis-stimulating agents claim that maintenance therapy of...
BackgroundDarbepoetin alfa is a new erythropoietic protein with a three-fold longer half-life than r...
BackgroundErythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney ...
BackgroundErythropoiesis-stimulating agents are used to treat anaemia in people with chronic kidney ...
Recombinant human erythropoietin (epoetin) has been available for the treatment of renal anemia for ...